128 related articles for article (PubMed ID: 16922812)
21. A convenient assay for mephenytoin 4-hydroxylase activity of human liver microsomal cytochrome P-450.
Shimada T; Shea JP; Guengerich FP
Anal Biochem; 1985 May; 147(1):174-9. PubMed ID: 4025815
[TBL] [Abstract][Full Text] [Related]
22. Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes.
Springer D; Staack RF; Paul LD; Kraemer T; Maurer HH
Xenobiotica; 2003 Oct; 33(10):989-98. PubMed ID: 14555336
[TBL] [Abstract][Full Text] [Related]
23. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes.
Kobayashi K; Chiba K; Yagi T; Shimada N; Taniguchi T; Horie T; Tani M; Yamamoto T; Ishizaki T; Kuroiwa Y
J Pharmacol Exp Ther; 1997 Feb; 280(2):927-33. PubMed ID: 9023308
[TBL] [Abstract][Full Text] [Related]
24. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
Yamazaki H; Shimada T
Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
[TBL] [Abstract][Full Text] [Related]
25. Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes.
Masimirembwa CM; Gustafsson LL; Dahl ML; Abdi YA; Hasler JA
Br J Clin Pharmacol; 1996 Apr; 41(4):344-6. PubMed ID: 8730982
[TBL] [Abstract][Full Text] [Related]
26. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Gentile DM; Verhoeven CH; Shimada T; Back DJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
[TBL] [Abstract][Full Text] [Related]
27. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
Emoto C; Iwasaki K
Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
[TBL] [Abstract][Full Text] [Related]
28. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
[TBL] [Abstract][Full Text] [Related]
29. Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes.
Relling MV; Evans WE; Fonné-Pfister R; Meyer UA
Cancer Res; 1989 Jan; 49(1):68-71. PubMed ID: 2908853
[TBL] [Abstract][Full Text] [Related]
30. Drug metabolism and variability among patients in drug response.
Wilkinson GR
N Engl J Med; 2005 May; 352(21):2211-21. PubMed ID: 15917386
[No Abstract] [Full Text] [Related]
31. Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A).
Yasumori T; Chen L; Nagata K; Yamazoe Y; Kato R
J Pharmacol Exp Ther; 1993 Jan; 264(1):89-94. PubMed ID: 8423554
[TBL] [Abstract][Full Text] [Related]
32. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.
Olesen OV; Linnet K
Drug Metab Dispos; 1997 Jun; 25(6):740-4. PubMed ID: 9193876
[TBL] [Abstract][Full Text] [Related]
33. CYP2C19-mediated (S)-mephenytoin 4'-hydroxylation assayed by high-performance liquid chromatography with radiometric detection.
Crespi CL; Chang TK; Waxman DJ
Methods Mol Biol; 2006; 320():115-9. PubMed ID: 16719381
[TBL] [Abstract][Full Text] [Related]
34. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
35. Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes.
Liu ZQ; Shu Y; Huang SL; Wang LS; He N; Zhou HH
Acta Pharmacol Sin; 2001 Jan; 22(1):85-90. PubMed ID: 11730569
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.
Salsali M; Holt A; Baker GB
Cell Mol Neurobiol; 2004 Feb; 24(1):63-76. PubMed ID: 15049511
[TBL] [Abstract][Full Text] [Related]
37. Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes.
Cai X; Wang RW; Edom RW; Evans DC; Shou M; Rodrigues AD; Liu W; Dean DC; Baillie TA
Drug Metab Dispos; 2004 Jun; 32(6):584-6. PubMed ID: 15155548
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
39. Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes): application to the chiral metabolism of mephenytoin and methadone.
Prost F; Thormann W
Electrophoresis; 2003 Aug; 24(15):2577-87. PubMed ID: 12900870
[TBL] [Abstract][Full Text] [Related]
40. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F
Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
